Weekly carboplatin and VM-26 for elderly patients with small-cell lung cancer

Details

Serval ID
serval:BIB_A3801117ED00
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Weekly carboplatin and VM-26 for elderly patients with small-cell lung cancer
Journal
Annals of Oncology
Author(s)
Michel  G., Leyvraz  S., Bauer  J., Aapro  M., Stahel  R., Alberto  P.
ISSN
0923-7534 (Print)
Publication state
Published
Issued date
04/1994
Volume
5
Number
4
Pages
369-70
Notes
Clinical Trial
Clinical Trial, Phase II
Journal Article --- Old month value: Apr
Abstract
BACKGROUND: Elderly patients are excluded from chemotherapy trials, even though they represent 25% of those with small cell lung cancer. An effective chemotherapy regimen with limited toxicity should be developed with the aim not only of increasing the survival of these patients, but also of improving their quality of life and their independence. PATIENTS AND METHODS: Twenty-four patients with a median age of 72 years and small-cell lung cancer (SCLC) were included in the trial. Chemotherapy consisted of a weekly intravenous regimen of Carboplatin 80 mg/m2 and Teniposide 80 mg/m2 administered on an outpatient basis. RESULTS: Eight patients had limited and 16 extensive disease. After a median of 12 chemotherapy courses (2-31) the overall response rate was 66.7% (95% Cl: 44.7-84.4), with 5 patients in complete and 11 in partial remission. The median overall survival was 33 weeks, with 4 patients alive at more than one year. Improvement of symptoms occurred in 86% of patients. Toxicity, mainly hematological, was moderate. CONCLUSIONS: Weekly Carboplatin and VM-26 is an effective and non-toxic regimen for elderly patients, leading to results similar to those obtained with a more intensive regimen in a younger age group.
Keywords
Aged Aged, 80 and over Antineoplastic Combined Chemotherapy Protocols/*administration & dosage/adverse effects Carboplatin/administration & dosage/adverse effects Carcinoma, Small Cell/*drug therapy Drug Administration Schedule Female Humans Lung Neoplasms/*drug therapy Male Teniposide/administration & dosage/adverse effects
Pubmed
Web of science
Create date
28/01/2008 8:31
Last modification date
20/08/2019 15:09
Usage data